Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

Similar articles for PubMed (Select 20639524)

1.

Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection.

Bruno CJ, Jacobson JM.

J Antimicrob Chemother. 2010 Sep;65(9):1839-41. doi: 10.1093/jac/dkq261. Epub 2010 Jul 17.

2.

Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults.

Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST.

Antimicrob Agents Chemother. 2009 Feb;53(2):450-7. doi: 10.1128/AAC.00942-08. Epub 2008 Nov 17.

3.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
4.

Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.

Dimitrov A.

Curr Opin Investig Drugs. 2007 Aug;8(8):653-61. Review.

PMID:
17668367
5.

Clinical development of microbicides for the prevention of HIV infection.

D'Cruz OJ, Uckun FM.

Curr Pharm Des. 2004;10(3):315-36. Review.

PMID:
14754390
6.

Anti-HIV agents targeting the interaction of gp120 with the cellular CD4 receptor.

Vermeire K, Schols D.

Expert Opin Investig Drugs. 2005 Oct;14(10):1199-212. Review.

PMID:
16185162
7.

Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.

Toma J, Weinheimer SP, Stawiski E, Whitcomb JM, Lewis ST, Petropoulos CJ, Huang W.

J Virol. 2011 Apr;85(8):3872-80. doi: 10.1128/JVI.02237-10. Epub 2011 Feb 2.

8.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

9.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
10.

Emerging drug targets for antiretroviral therapy.

Reeves JD, Piefer AJ.

Drugs. 2005;65(13):1747-66. Review.

PMID:
16114975
11.

Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection.

Klibanov OM.

Curr Opin Investig Drugs. 2009 Aug;10(8):845-59. Review.

PMID:
19649929
13.

Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection.

Klibanov OM, Williams SH, Iler CA.

Curr Opin Investig Drugs. 2010 Aug;11(8):940-50.

PMID:
20721836
14.

Epitope mapping of ibalizumab, a humanized anti-CD4 monoclonal antibody with anti-HIV-1 activity in infected patients.

Song R, Franco D, Kao CY, Yu F, Huang Y, Ho DD.

J Virol. 2010 Jul;84(14):6935-42. doi: 10.1128/JVI.00453-10. Epub 2010 May 12.

15.

HIV-1 entry and entry inhibitors as therapeutic agents.

Starr-Spires LD, Collman RG.

Clin Lab Med. 2002 Sep;22(3):681-701. Review.

PMID:
12244592
16.

Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

Wainberg MA, Sawyer JP, Montaner JS, Murphy RL, Kuritzkes DR, Raffi F.

Antivir Ther. 2005;10(1):13-28. Review.

PMID:
15751760
17.

[Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].

Rey D, Schmitt MP, Hess-Kempf G, Krantz V, Partisani M, Bernard-Henry C, Lang JM.

Pathol Biol (Paris). 2001 Sep;49(7):559-66. French.

PMID:
11642019
18.

Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

Ribera E, Rodríguez-Pardo D, Rubio M, Soler A, Pedrol E, Blanco JL, González A, Crespo M, Falcó V, Ocaña I, Deig E, Miró JM, Pahissa A.

Antivir Ther. 2005;10(5):605-14.

PMID:
16152754
19.

A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

AIDS. 1999 Dec 3;13(17):2377-88.

PMID:
10597779
20.

[Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update January 2007)].

Panel de expertos de GESIDA; Plan Nacional sobre el Sida.

Enferm Infecc Microbiol Clin. 2007 Jan;25(1):32-53. Spanish.

PMID:
17261244
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk